Research programme: metabotropic glutamate receptor 4 modulators - Addex Therapeutics

Drug Profile

Research programme: metabotropic glutamate receptor 4 modulators - Addex Therapeutics

Alternative Names: ADX 88178; mGluR4 modulators - Addex Therapeutics; mGluR4 PAM; VU0003423

Latest Information Update: 09 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Addex Pharmaceuticals; Merck & Co
  • Developer Addex Therapeutics; Ecole Polytechnique Federale de Lausanne.; University of Lausanne
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 agonists; Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Autistic disorder; Cocaine abuse; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 07 Dec 2016 Preclinical trials in Autistic disorder in Switzerland (unspecified route) (Addex Therapeutics pipeline, December 2016)
  • 11 Oct 2016 Preclinical trials in Cocaine abuse in Switzerland (PO)
  • 23 Nov 2015 Addex Therapeutics and CHUV-Lausanne University (UNIL) collaborate to advance allosteric modulators for neurodegenerative disorders and psychiatric diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top